{
  "company": {
    "ticker": "BIIB",
    "name": "Biogen Inc.",
    "category": [
      "Biotech"
    ],
    "sector": "Healthcare",
    "subCategory": "Biotech",
    "cik": "0000875045"
  },
  "reports": [
    {
      "filing": {
        "accessionNumber": "0000875045-25-000049",
        "filingDate": "2025-10-30",
        "reportDate": "2025-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504525000049/biib-20250930.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 1846.9,
        "netIncome": 466.5,
        "operatingCashFlow": 1692.7,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 43.8,
        "geographicBreakdown": {
          "US": 50.7,
          "RestOfWorld": 49.3
        },
        "capexAmount": 109.9,
        "capexGrowth": null,
        "partnerships": [
          "Eisai (LEQEMBI)",
          "Genentech (anti-CD20 programs)",
          "Supernus (ZURZUVAE)",
          "Samsung",
          "Human Immunology Biosciences",
          "Ionis Pharmaceuticals",
          "Alcyone Therapeutics"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Inflation Reduction Act impacts",
          "Medicare Part D redesign"
        ],
        "aiInvestmentMentioned": true,
        "priorGuidanceHit": null,
        "managementTone": "neutral",
        "overallSentiment": "neutral",
        "summary": "Biogen delivered stable quarterly performance with modest growth in key MS and rare disease franchises. The company continues its strategic restructuring program and is making selective investments in pipeline and AI technologies while managing expenses.",
        "keyQuotes": [
          "We remain focused on our long-term strategy of discovering and developing innovative therapies for serious and complex diseases.",
          "Our Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025."
        ],
        "marketData": {
          "priceOnEarningsDate": 140.0800018310547,
          "priceAfter7Days": 152.2100067138672,
          "priceChangePercent": 8.65934089395719,
          "managementToneScore": 45,
          "earningsBeatScore": 50,
          "priceActionScore": 80,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 59,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2025",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2025,
        "fiscalQuarter": 3,
        "fiscalYear": 2025,
        "quarter": "Q3 2025",
        "reportDate": "2025-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-25-000033",
        "filingDate": "2025-07-31",
        "reportDate": "2025-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504525000033/biib-20250630.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 1878.7,
        "netIncome": 634.8,
        "operatingCashFlow": 420.2,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 43.9,
        "geographicBreakdown": {
          "US": 50.1,
          "RestOfWorld": 49.9
        },
        "capexAmount": 63.7,
        "capexGrowth": null,
        "partnerships": [
          "Eisai (LEQEMBI)",
          "Genentech (anti-CD20 therapies)",
          "Sage (ZURZUVAE)",
          "HI-Bio acquisition",
          "Samsung"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Potential IRA Medicare pricing impact",
          "Generic/biosimilar competition"
        ],
        "aiInvestmentMentioned": true,
        "priorGuidanceHit": null,
        "managementTone": "confident",
        "overallSentiment": "neutral",
        "summary": "Biogen delivered stable quarterly performance with modest revenue of $1.88B and net income of $634.8M. The company continues to focus on cost reduction via its Fit for Growth program while making strategic investments in pipeline and emerging technologies.",
        "keyQuotes": [
          "We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases",
          "The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025"
        ],
        "marketData": {
          "priceOnEarningsDate": 125.58999633789062,
          "priceAfter7Days": 130.1300048828125,
          "priceChangePercent": 3.614944404255986,
          "managementToneScore": 70,
          "earningsBeatScore": 50,
          "priceActionScore": 65,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 57,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2025",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2025,
        "fiscalQuarter": 2,
        "fiscalYear": 2025,
        "quarter": "Q2 2025",
        "reportDate": "2025-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-25-000018",
        "filingDate": "2025-05-01",
        "reportDate": "2025-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504525000018/biib-20250331.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 2431,
        "netIncome": 240.5,
        "operatingCashFlow": 259.3,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 39.9,
        "geographicBreakdown": {
          "US": 30.9,
          "RestOfWorld": 69.1
        },
        "capexAmount": 37.1,
        "capexGrowth": null,
        "partnerships": [
          "Eisai (Alzheimer's collaboration)",
          "Genentech (anti-CD20 therapeutic programs)",
          "Samsung Bioepis (biosimilars)",
          "HI-Bio (acquired in July 2024)",
          "Samsung",
          "Roche Group Genentech"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Potential impact of IRA Medicare Part D redesign",
          "Healthcare reform measures"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "neutral",
        "summary": "Biogen delivered stable quarterly performance with revenue of $2.43B and net income of $240.5M, reflecting continued focus on cost management through its Fit for Growth program. The company maintains a cautious outlook amid ongoing restructuring and regulatory challenges.",
        "keyQuotes": [
          "We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases",
          "The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025"
        ],
        "marketData": {
          "priceOnEarningsDate": 136.83999633789062,
          "priceAfter7Days": 119.19000244140625,
          "priceChangePercent": -12.898271242935675,
          "managementToneScore": 25,
          "earningsBeatScore": 50,
          "priceActionScore": 5,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 34,
          "compositeSentiment": "bearish"
        }
      },
      "quarter": "Q1 2025",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2025,
        "fiscalQuarter": 1,
        "fiscalYear": 2025,
        "quarter": "Q1 2025",
        "reportDate": "2025-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-25-000009",
        "filingDate": "2025-02-12",
        "reportDate": "2024-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504525000009/biib-20241231.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "reducing",
        "revenue": null,
        "netIncome": null,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Facing generic competition for TECFIDERA and TYSABRI",
        "customerConcentration": null,
        "geographicBreakdown": {
          "US": null,
          "Europe": null,
          "Asia": null,
          "Other": null
        },
        "capexAmount": null,
        "capexGrowth": null,
        "partnerships": [
          "Eisai (LEQEMBI)",
          "Sage (ZURZUVAE)",
          "Genentech (anti-CD20 therapies)",
          "Samsung Bioepis (biosimilars)",
          "Samsung",
          "Reata Pharmaceuticals",
          "Ionis Pharmaceuticals"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Drug pricing pressures",
          "Increased regulatory scrutiny",
          "Potential Medicare drug price negotiations"
        ],
        "aiInvestmentMentioned": true,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Biogen faces significant headwinds from generic competition, challenging pricing environment, and ongoing strategic repositioning focused on neurology and specialized immunology.",
        "keyQuotes": [
          "We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases.",
          "Multiple TECFIDERA generic entrants are now in North America, Brazil and certain European countries and have deeply discounted prices"
        ],
        "marketData": {
          "priceOnEarningsDate": 152.9199981689453,
          "priceAfter7Days": 153.14999389648438,
          "priceChangePercent": 0.15040264863524538,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 55,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 47,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2024",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2024,
        "fiscalQuarter": 4,
        "fiscalYear": 2024,
        "quarter": "Q4 2024",
        "reportDate": "2024-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-24-000032",
        "filingDate": "2024-10-30",
        "reportDate": "2024-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504524000032/biib-20240930.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 1769.4,
        "netIncome": 388.5,
        "operatingCashFlow": 2114.6,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 40.7,
        "geographicBreakdown": {
          "unitedStates": 45.9,
          "restOfWorld": 54.1
        },
        "capexAmount": 114.4,
        "capexGrowth": null,
        "partnerships": [
          "Genentech anti-CD20 therapeutic programs",
          "Eisai LEQEMBI collaboration",
          "Samsung Bioepis biosimilars",
          "Samsung",
          "Reata Pharmaceuticals Inc.",
          "Ionis Pharmaceuticals Inc."
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "neutral",
        "overallSentiment": "neutral",
        "summary": "Biogen delivered steady quarterly performance with $1.77B in revenue and $388.5M net income. The company continues strategic restructuring efforts through its Fit for Growth program and recently completed the HI-Bio acquisition to strengthen its immunology pipeline.",
        "keyQuotes": [
          "We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases.",
          "The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025"
        ],
        "marketData": {
          "priceOnEarningsDate": 193.83999633789062,
          "priceAfter7Days": 183.33999633789062,
          "priceChangePercent": -5.416838732135039,
          "managementToneScore": 50,
          "earningsBeatScore": 50,
          "priceActionScore": 25,
          "guidanceAccuracyScoreWeighted": 75,
          "compositeSentimentScore": 48,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2024",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2024,
        "fiscalQuarter": 3,
        "fiscalYear": 2024,
        "quarter": "Q3 2024",
        "reportDate": "2024-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-24-000025",
        "filingDate": "2024-08-01",
        "reportDate": "2024-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504524000025/biib-20240630.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 2464.9,
        "netIncome": 583.6,
        "operatingCashFlow": 1179,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 37.7,
        "geographicBreakdown": {
          "US": 34.4,
          "RestOfWorld": 65.6
        },
        "capexAmount": 79.4,
        "capexGrowth": null,
        "partnerships": [
          "Eisai - LEQEMBI collaboration",
          "Genentech - Anti-CD20 therapeutic programs",
          "Samsung Bioepis - Biosimilars",
          "Samsung",
          "Ionis Pharmaceuticals",
          "Reata Pharmaceuticals",
          "Human Immunology Biosciences"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "neutral",
        "overallSentiment": "neutral",
        "summary": "Biogen delivered stable quarterly performance with modest revenue growth. The company continues its cost reduction efforts through the Fit for Growth program while maintaining a diversified portfolio across multiple therapeutic areas.",
        "keyQuotes": [
          "We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases.",
          "The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by the end of 2025"
        ],
        "marketData": {
          "priceOnEarningsDate": 231.77000427246094,
          "priceAfter7Days": 228.07000732421875,
          "priceChangePercent": -1.5964088881374818,
          "managementToneScore": 50,
          "earningsBeatScore": 50,
          "priceActionScore": 45,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 49,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2024",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2024,
        "fiscalQuarter": 2,
        "fiscalYear": 2024,
        "quarter": "Q2 2024",
        "reportDate": "2024-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-24-000016",
        "filingDate": "2024-04-24",
        "reportDate": "2024-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504524000016/biib-20240331.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 1711.9,
        "netIncome": 393.4,
        "operatingCashFlow": 553.2,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 37.3,
        "geographicBreakdown": {
          "US": 43.6,
          "RestOfWorld": 56.4
        },
        "capexAmount": 45.9,
        "capexGrowth": null,
        "partnerships": [
          "Eisai (LEQEMBI)",
          "Genentech (anti-CD20 therapies)",
          "Sage (ZURZUVAE)",
          "Samsung",
          "Roche",
          "Reata Pharmaceuticals"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "neutral",
        "overallSentiment": "neutral",
        "summary": "Biogen delivered stable financial performance in Q1 2024, with modest revenue decline offset by cost management efforts. The company continues strategic focus on neurology and rare disease therapies while implementing cost reduction initiatives.",
        "keyQuotes": [
          "We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases.",
          "We initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs"
        ],
        "marketData": {
          "priceOnEarningsDate": 214.8300018310547,
          "priceAfter7Days": 204.9499969482422,
          "priceChangePercent": -4.598987477820846,
          "managementToneScore": 50,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 46,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q1 2024",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2024,
        "fiscalQuarter": 1,
        "fiscalYear": 2024,
        "quarter": "Q1 2024",
        "reportDate": "2024-03-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-24-000009",
        "filingDate": "2024-02-14",
        "reportDate": "2023-12-31",
        "form": "10-K",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504524000009/biib-20231231.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "reducing",
        "revenue": 4471.8,
        "netIncome": 1468.2,
        "operatingCashFlow": null,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Facing significant generic competition for TECFIDERA",
        "customerConcentration": null,
        "geographicBreakdown": null,
        "capexAmount": 195,
        "capexGrowth": null,
        "partnerships": [
          "Eisai (LEQEMBI)",
          "Sage (ZURZUVAE)",
          "Genentech (anti-CD20 therapies)",
          "Samsung",
          "Roche Group Genentech",
          "Eisai",
          "Reata Pharmaceuticals"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Potential drug price negotiations under Inflation Reduction Act",
          "Complex international regulatory environments"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "bearish",
        "summary": "Biogen is experiencing significant revenue pressures from generic competition, particularly for TECFIDERA. The company is exploring strategic options and focusing on new product launches like LEQEMBI and SKYCLARYS while managing manufacturing capacity challenges.",
        "keyQuotes": [
          "We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases.",
          "The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and we expect that TECFIDERA revenue will continue to decline in the future."
        ],
        "marketData": {
          "priceOnEarningsDate": 267.7099914550781,
          "priceAfter7Days": 257.9800109863281,
          "priceChangePercent": -3.634522722093731,
          "managementToneScore": 5,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 41,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q4 2023",
      "quarterInfo": {
        "calendarQuarter": 4,
        "calendarYear": 2023,
        "fiscalQuarter": 4,
        "fiscalYear": 2023,
        "quarter": "Q4 2023",
        "reportDate": "2023-12-31"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-23-000038",
        "filingDate": "2023-11-08",
        "reportDate": "2023-09-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504523000038/biib-20230930.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "reducing",
        "revenue": 1805.2,
        "netIncome": -68.1,
        "operatingCashFlow": 1534.7,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 37.4,
        "geographicBreakdown": {
          "US": 44,
          "RestOfWorld": 56
        },
        "capexAmount": 211.8,
        "capexGrowth": null,
        "partnerships": [
          "Eisai (LEQEMBI)",
          "Genentech (anti-CD20 therapies)",
          "Sage Therapeutics (ZURZUVAE)",
          "Samsung"
        ],
        "supplyChainStatus": "tight",
        "regulatoryHeadwinds": [
          "Inflation Reduction Act pricing pressures",
          "Medicare/Medicaid reimbursement challenges"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "neutral",
        "summary": "Biogen experienced revenue decline and a quarterly net loss, driven by challenges in multiple sclerosis franchise and ongoing restructuring. The company completed the Reata acquisition, adding Friedreich's Ataxia treatment SKYCLARYS, and continues cost reduction initiatives.",
        "keyQuotes": [
          "We initiated additional cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness.",
          "The Fit for Growth program is expected to generate approximately $1.0 billion in gross operating expense savings by 2025"
        ],
        "marketData": {
          "priceOnEarningsDate": 252.86000061035156,
          "priceAfter7Days": 264.2099914550781,
          "priceChangePercent": 4.488646214241098,
          "managementToneScore": 25,
          "earningsBeatScore": 50,
          "priceActionScore": 65,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 52,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q3 2023",
      "quarterInfo": {
        "calendarQuarter": 3,
        "calendarYear": 2023,
        "fiscalQuarter": 3,
        "fiscalYear": 2023,
        "quarter": "Q3 2023",
        "reportDate": "2023-09-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-23-000030",
        "filingDate": "2023-07-25",
        "reportDate": "2023-06-30",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504523000030/biib-20230630.htm"
      },
      "insights": {
        "guidanceTone": "cautious",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "weak",
        "headcountTrend": "reducing",
        "revenue": 2456,
        "netIncome": 593.3,
        "operatingCashFlow": 942.3,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": "Multiple Sclerosis product revenues declining",
        "customerConcentration": 36.3,
        "geographicBreakdown": {
          "US": 0.61,
          "RestOfWorld": 0.39
        },
        "capexAmount": 137.6,
        "capexGrowth": null,
        "partnerships": [
          "Eisai (LEQEMBI)",
          "Genentech (Anti-CD20 therapies)",
          "Samsung",
          "Roche Group Genentech"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "FDA approvals",
          "Biosimilar competition"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": null,
        "managementTone": "defensive",
        "overallSentiment": "neutral",
        "summary": "Biogen experienced revenue and earnings decline driven by MS product weakness. Cost reduction initiatives ongoing, with continued focus on strategic partnerships and new product launches.",
        "keyQuotes": [
          "We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases",
          "We initiated additional cost saving measures as part of our Fit for Growth initiative"
        ],
        "marketData": {
          "priceOnEarningsDate": 284.8500061035156,
          "priceAfter7Days": 275.07000732421875,
          "priceChangePercent": -3.4333854905176953,
          "managementToneScore": 25,
          "earningsBeatScore": 50,
          "priceActionScore": 35,
          "guidanceAccuracyScoreWeighted": 50,
          "compositeSentimentScore": 43,
          "compositeSentiment": "neutral"
        }
      },
      "quarter": "Q2 2023",
      "quarterInfo": {
        "calendarQuarter": 2,
        "calendarYear": 2023,
        "fiscalQuarter": 2,
        "fiscalYear": 2023,
        "quarter": "Q2 2023",
        "reportDate": "2023-06-30"
      },
      "analyzedSuccessfully": true
    },
    {
      "filing": {
        "accessionNumber": "0000875045-23-000016",
        "filingDate": "2023-04-25",
        "reportDate": "2023-03-31",
        "form": "10-Q",
        "url": "https://www.sec.gov/Archives/edgar/data/875045/000087504523000016/biib-20230331.htm"
      },
      "insights": {
        "guidanceTone": "neutral",
        "guidanceDirection": "maintained",
        "bookingsGrowth": null,
        "pricingPower": "moderate",
        "headcountTrend": "reducing",
        "revenue": 2463,
        "netIncome": 387.6,
        "operatingCashFlow": 455.3,
        "freeCashFlow": null,
        "daysalesOutstanding": null,
        "deferredRevenue": null,
        "marketShareMention": null,
        "customerConcentration": 34.7,
        "geographicBreakdown": {
          "US": 46.5,
          "RestOfWorld": 53.5
        },
        "capexAmount": 66.6,
        "capexGrowth": null,
        "partnerships": [
          "Eisai (LEQEMBI)",
          "Genentech (Anti-CD20 programs)",
          "Samsung",
          "Roche Group Genentech",
          "Eisai",
          "Centers for Medicare and Medicaid Services"
        ],
        "supplyChainStatus": "normal",
        "regulatoryHeadwinds": [
          "Inflation Reduction Act"
        ],
        "aiInvestmentMentioned": false,
        "priorGuidanceHit": true,
        "managementTone": "confident",
        "overallSentiment": "bullish",
        "summary": "Biogen delivered a solid Q1 2023 with robust revenue and earnings, driven by continued strength in multiple sclerosis portfolio and new collaboration revenues. The company is managing costs through restructuring and maintaining a confident outlook.",
        "keyQuotes": [
          "We are focused on advancing our pipeline in neurology, neuropsychiatry, specialized immunology and rare diseases.",
          "We collaborate with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease"
        ],
        "marketData": {}
      },
      "quarter": "Q1 2023",
      "quarterInfo": {
        "calendarQuarter": 1,
        "calendarYear": 2023,
        "fiscalQuarter": 1,
        "fiscalYear": 2023,
        "quarter": "Q1 2023",
        "reportDate": "2023-03-31"
      },
      "analyzedSuccessfully": true
    }
  ],
  "totalFetched": 12,
  "successfulAnalyses": 11,
  "lastUpdated": "2025-11-26T06:26:44.116Z"
}